参考文献
[1]RESHMI G, PILLAI M R. Beyond HPV: oncomirs as new players in cervical cancer[J]. FEBS Letters, 2008.
[2]MATSUDA T, et al. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project[J]. Japanese Journal of Clinical Oncology, 2011.
[3]BANNO K, et al. MicroRNAs in endometrial cancer[J]. Int J Clin Onco, 2013.
[4]TORRES A, et al. MicroRNAs and their role in gynecological tumors[J]. Med Res Reviews, 2011.
[5]ZIMMERMANN H, et al. The human papillomavirus type 16 E6 oncoprotein can down- regulate P53 activity by targeting the transcriptional coactivator CBP/p300[J]. J Virol, 1999.
[6]PATEL D, et al. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300[J]. EMBO J, 1999.
[7]SHIN M K, et al. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis[J]. Cancer Res, 2009.
[8]LI W, et al. The physical state of HPV 16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma[J]. J Cancer Res Clin Oncol, 2008.
[9]LU J, et al. MicroRNA expression profiles classify human cancers. Nature, 2005.
[10]GEORGES S A, et al. Coordinatedregulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215[J]. Cancer Res, 2008.
[11]BRAUN C J, et al. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest[J]. Cancer Res, 2008.
[12]YAN H L, et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis[J]. EMBO, 2009.
[13]PARK S Y, et al. miR-29 miRNAs activate p53 by targeting p85a and CDC42[J]. Nature Struct Mol Bio, 2009.
[14]FORNARI F, et al. MiR-122/cyclin Gl interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells[J]. Cancer Res, 2009.
[15]LE M T, et al. MicroRNA-125b is a novel negative regulator of p53[J]. Genes Dev, 2009.
[16]PAPAGIANNAKOPOULOS T, et al. Micro-RNA-21 targets a network of key tumor- suppressive pathways in glioblastoma cells[J]. Cancer Res, 2008.
[17]Wei Q, et al. MiR-17-Sp targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells[J]. IUBMB Life, 2012.
[18]CUI F, et al. MiR-125b inhibits tumor growth and promotes apoptosis of cervix cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta[J]. CeII Phy Bio, 2012.
[19]YAO Q, et al. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells[J]. Bo Bio Res Com, 2009.
[20]YAO T, et al. MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20[J]. Bio Bio Acta, 2012.
[21]LONG M J, et al. MicroRNA-l0a targets CHLl and promotes cell growth, migration and invasion in human cervical cancer cells[J]. Cancer Let.2012.
[22]XU X M, et al. MicroRNA-19a and-19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5[J]. Cancer Let, 2012.
[23]KANG H W, et al. miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells[J]. FEBS Let, 2012.
[24]QIN W, et al. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways[J]. Qncogene, 2011.
[25]VALADI H, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells[J]. Nature Cell Bio, 2007.
[26]PHUAH N H, et al. Alterations of microRNA expression patterns in human cervical carcinoma cells (Ca Ski) toward-acetoxychavicol acetate and cisplatin[J]. Rep Scien, 2013.
[27]LEI C, et al. Up-regulated miR155 reverses he epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in humanCaski cervical cancer cells[J]. PIoS One, 2012.
[28]WANG F, et al. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of Bc1212 in cervical cancer cells[J]. FEBS Let, 2013.
[29]LI J, et al. MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer[J]. Int J Mol Sci, 2012.
[30]SHEN Y, et al. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer[J]. Bri J Cancer, 2013.
[31]KE C, et al. MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the proapoptotic PRKCD gene. Oncogene, 2013.